Authors: Murphy, GP Snow, PB Brandt, J Elgamal, A Brawer, MK

Citation: Gp. Murphy et al., Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint (R) scintiscans, PROSTATE, 42(2), 2000, pp. 145-149

Authors: Awaad, Y Tayem, H Elgamal, A Coyne, MF

Citation: Y. Awaad et al., Treatment of childhood myoclonus with botulinum toxin type A, J CHILD NEU, 14(12), 1999, pp. 781-786

Authors: Tjoa, BA Simmons, SJ Elgamal, A Rogers, M Ragde, H Kenny, GM Troychak, MJ Boynton, AL Murphy, GP

Citation: Ba. Tjoa et al., Follow-up evaluation of a phase II prostate cancer vaccine trial, PROSTATE, 40(2), 1999, pp. 125-129

Authors: Simmons, SJ Tjoa, BA Rogers, M Elgamal, A Kenny, GM Ragde, H Troychak, MJ Boynton, AL Murphy, GP

Citation: Sj. Simmons et al., GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial, PROSTATE, 39(4), 1999, pp. 291-297

Authors: Murphy, GP Tjoa, BA Simmons, SJ Ragde, H Rogers, M Elgamal, A Kenny, GM Troychak, MJ Salgaller, ML Boynton, AL

Citation: Gp. Murphy et al., Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment, PROSTATE, 39(1), 1999, pp. 54-59

Authors: Murphy, GP Tjoa, BA Simmons, SJ Jarisch, J Bowes, VA Ragde, H Rogers, M Elgamal, A Kenny, GM Cobb, OE Ireton, RC Troychak, MJ Salgaller, ML Boynton, AL

Citation: Gp. Murphy et al., Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, PROSTATE, 38(1), 1999, pp. 73-78